Reduces LDL-C and ApoB exposure and, for appropriately selected therapies and populations, lowers cardiovascular-event risk.
LONGEVITY & HEALTHY AGING / PRACTITIONER-GUIDED
Cholesterol-lowering medications
EvidenceEvidence in contexti
Strong outcome evidence supports established therapies for appropriate primary- and secondary-prevention populations.
RegulatoryProduct-specifici
Prescription required; drug- and indication-specific FDA labeling

Strong outcome evidence supports established therapies for appropriate primary- and secondary-prevention populations.
Prescription required; drug- and indication-specific FDA labeling
WHO MAY BE CONSIDERED
Eligibility starts with your complete health context.
- ✓LDL-C or ApoB burden and overall risk justify medication
- ✓Family history, diabetes, kidney disease, imaging and prior events are considered
- ✓Response, adherence and adverse effects can be monitored
WHAT A PRACTITIONER REVIEWS
The information that shapes the decision.
- Fasting or nonfasting lipid profile and ApoB when useful
- Personal and family cardiovascular history
- Pregnancy context, liver history, muscle symptoms and interacting drugs
IMPORTANT SAFETY INFORMATION
Reasons treatment may not be appropriate.
- !Therapy should be matched to baseline risk and expected absolute benefit.
- !Muscle symptoms, liver concerns and interactions deserve structured review rather than automatic discontinuation.
- !Pregnancy and lactation decisions require product-specific clinical guidance.
ORIGINAL SOURCES
Review the evidence behind the option.
YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools